Bausch + Lomb Corporation BLCO

SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL)Secures scalable commercial IOL manufacturing capacity for its Phase 3 lead product candidate, the BIM-IOL SystemAccelerates pathway to adding premium lens options into its IOL-based drug delivery systemSpyGlass Pharma intends to continue supporting AVS customers and licensees utilizing their proprietary IOL

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Robinson Pharma, Inc. (RPI), a premier full-service contract manufacturer of dietary supplements and nutraceuticals, is proud to announce that it has been honored by Bausch + Lomb with the "Above and Beyond" Supplier Award for the month of September 2026. This prestigious recognition underscores the company's sustained commitment to operational excellence, quality assurance, and the reliable delivery of high-volume manufacturing solutions.

VAUGHAN, Ontario, September 11, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company’s next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for premium cataract, LASIK flap and corneal therapeutic surgeries while simultaneous

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

VAUGHAN, Ontario, September 02, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered both good distance and functional intermediate vision, thus meetin

VAUGHAN, Ontario, September 01, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around dry eye and its association with perimenopause and menopause. The survey found that dry eye remains one of the least recognized symptoms experienced during these stages of life.

Bausch + Lomb stock has delivered a 17.2% return over the past year, yet several valuation checks still flag the shares as cheap relative to an intrinsic value estimate and to market multiples. For investors, the puzzle is why a stock with a high value score and an intrinsic estimate that screens as undervalued is not pricing in more of that potential. The 17.2% 1 year return suggests Bausch + Lomb has already rewarded patient holders, but the move has not erased what some models see as a...

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 24.9% over the past six months, topping the S&P 500 by 13.3 percentage points.

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Bausch + Lomb (NYSE:BLCO) and its peers.

Bausch + Lomb (BLCO) said late Monday it plans to advance two of its pharmaceutical pipeline assets

VAUGHAN, Ontario, August 24, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results.